{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:03:32Z","timestamp":1784937812336,"version":"3.55.0"},"reference-count":193,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.autrev.2018.02.013","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T06:29:31Z","timestamp":1531290571000},"page":"854-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Support of precision medicine through risk-stratification in autoimmune liver diseases \u2013 histology, scoring systems, and non-invasive markers"],"prefix":"10.1016","volume":"17","author":[{"given":"Lars","family":"Bossen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Gerussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Lygoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Mells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2018.02.013_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000440705","article-title":"Worldwide incidence of autoimmune liver disease","volume":"33","author":"Jepsen","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0010","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.02.013_bb0015","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.02.013_bb0020","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0140-6736(12)62163-1","article-title":"Autoimmune hepatitis","volume":"382","author":"Heneghan","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.02.013_bb0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4254\/wjh.v8.i28.1157","article-title":"Cirrhosis and autoimmune liver disease: current understanding","volume":"8","author":"Liberal","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0035","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"European Association for the Study of the Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2013.09.020","article-title":"Autoimmune liver disease, autoimmunity and liver transplantation","volume":"60","author":"Carbone","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2018.02.013_bb0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000440831","article-title":"Overlap syndromes","volume":"33","author":"Chazouilleres","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOG.0000000000000058","article-title":"Primary biliary cirrhosis in 2014","volume":"30","author":"Flores","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1665-2681(19)30838-5","article-title":"Predicting outcome in primary biliary cirrhosis","volume":"13","author":"Lammers","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0070","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s00535-013-0903-1","article-title":"Biochemical response to ursodeoxycholic acid predicts survival in a north American cohort of primary biliary cirrhosis patients","volume":"49","author":"Lammert","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0075","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0080","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving Ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0085","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.02.013_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis","volume":"308","author":"Roll","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.02.013_bb0105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1478-3231.2010.02366.x","article-title":"A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single Centre","volume":"31","author":"Floreani","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0110","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0115","doi-asserted-by":"crossref","first-page":"S805","DOI":"10.1016\/S0168-8278(15)31394-5","article-title":"Histological stage is relevant for risk-stratification in primary biliary cirrhosis, abstract P1198","volume":"62","author":"Carbone","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0120","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouilleres","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0130","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouilleres","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2009.616","article-title":"Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis","volume":"105","author":"Neuhauser","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0140","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/gut.49.2.276","article-title":"Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant","volume":"49","author":"Vleggaar","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.02.013_bb0145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0150","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"European Association for Study of the Liver, Asociacion Latinoamericana para el Estudio del H","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0155","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1055\/s-0043-103952","article-title":"EFSUMB guidelines and recommendations on the clinical use of liver ultrasound Elastography, update 2017 (long version)","volume":"38","author":"Dietrich","year":"2017","journal-title":"Ultraschall Med"},{"key":"10.1016\/j.autrev.2018.02.013_bb0160","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.crad.2014.03.019","article-title":"Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis: a preliminary study","volume":"69","author":"Zhang","year":"2014","journal-title":"Clin Radiol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0165","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay","volume":"48","author":"Mayo","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0170","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-008-0150-6","article-title":"The value of antinuclear antibodies in primary biliary cirrhosis","volume":"8","author":"Gao","year":"2008","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.autrev.2018.02.013_bb0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1872-034X.2010.00631.x","article-title":"Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): the HLA-DRB1polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC","volume":"40","author":"Nakamura","year":"2010","journal-title":"Hepatol Res"},{"key":"10.1016\/j.autrev.2018.02.013_bb0190","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/apt.13244","article-title":"Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis","volume":"42","author":"Guo","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.02.013_bb0200","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0035-1567831","article-title":"Genome-wide association studies in primary biliary cirrhosis","volume":"35","author":"Gulamhusein","year":"2015","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0205","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1161\/CIRCRESAHA.109.215616","article-title":"A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease","volume":"106","author":"Ding","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2018.02.013_bb0210","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1159\/000302738","article-title":"Association of a genetic variant in the ALOX5AP with higher risk of ischemic stroke: a case-control, meta-analysis and functional study","volume":"29","author":"Domingues-Montanari","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0215","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.1142447","article-title":"A common allele on chromosome 9 associated with coronary heart disease","volume":"316","author":"McPherson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.autrev.2018.02.013_bb0220","doi-asserted-by":"crossref","unstructured":"Alberts R, de Vries EMG, Goode EC, Jiang X, Sampaziotis F, Rombouts K, Bottcher K, et al. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut 2017;0:1\u20138. doi:https:\/\/doi.org\/10.1136\/gutjnl-2016-313598.","DOI":"10.1136\/gutjnl-2016-313598"},{"key":"10.1016\/j.autrev.2018.02.013_bb0225","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ng.3755","article-title":"Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease","volume":"49","author":"Lee","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2018.02.013_bb0230","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0240","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2013.10.020","article-title":"Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study","volume":"60","author":"Gronbaek","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0250","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/hep.27983","article-title":"Prediction of short- and long-term outcome in patients with autoimmune hepatitis","volume":"62","author":"Kirstein","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0255","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0260","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"EASL clinical practical guidelines on the management of acute (fulminant) liver failure","volume":"66","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0265","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2014.05.021","article-title":"Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome","volume":"61","author":"Yeoman","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0270","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2015.07.017","article-title":"Features and progression of asymptomatic autoimmune hepatitis in Italy","volume":"14","author":"Muratori","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(56)90003-1","article-title":"The problem of chronic liver disease in young women","volume":"21","author":"Bearn","year":"1956","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2018.02.013_bb0280","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: the bologna experience","volume":"50","author":"Muratori","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0285","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","article-title":"Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study","volume":"43","author":"Werner","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0290","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1440-1746.2010.06384.x","article-title":"Population-based epidemiology study of autoimmune hepatitis: a disease of older women?","volume":"25","author":"Ngu","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0295","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/apt.12563","article-title":"Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly","volume":"39","author":"Chen","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.02.013_bb0300","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2169\/internalmedicine.46.0420","article-title":"Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis","volume":"46","author":"Miyake","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2018.02.013_bb0305","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/hep.26290","article-title":"Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study","volume":"57","author":"Ngu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2013.08.004","article-title":"Autoimmune hepatitis: contrasts and comparisons in children and adults - a comprehensive review","volume":"46","author":"Floreani","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2018.02.013_bb0315","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0320","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.25658","article-title":"Long-term outcome of Japanese patients with type 1 autoimmune hepatitis","volume":"56","author":"Yoshizawa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0325","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2007.08.013","article-title":"Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis","volume":"48","author":"Al-Chalabi","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0330","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/egh.13.21","article-title":"Autoimmune hepatitis in diverse ethnic populations and geographical regions","volume":"7","author":"Czaja","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0335","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/j.1572-0241.2001.05272.x","article-title":"Autoimmune hepatitis in African Americans: presenting features and response to therapy","volume":"96","author":"Lim","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0340","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.50.5.713","article-title":"Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin","volume":"50","author":"Zolfino","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.02.013_bb0345","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1478-3231.2005.01088.x","article-title":"An unusual form of autoimmune hepatitis in young Somalian men","volume":"25","author":"D'Souza","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0350","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/hep.21884","article-title":"The impact of ethnicity on the natural history of autoimmune hepatitis","volume":"46","author":"Verma","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0355","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12072-016-9727-4","article-title":"Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients","volume":"10","author":"Than","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0360","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/j.1572-0241.2004.30444.x","article-title":"The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease","volume":"99","author":"Adams","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0365","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1007\/s10620-015-3795-5","article-title":"Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis-related liver disease","volume":"60","author":"Ravi","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2018.02.013_bb0370","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-016-4213-3","article-title":"Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease","volume":"61","author":"De Luca-Johnson","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2018.02.013_bb0375","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1665-2681(19)30914-7","article-title":"Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome","volume":"13","author":"Rigopoulou","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0380","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1086\/427285","article-title":"Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C","volume":"40","author":"Muratori","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0385","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3109\/00365521.2013.772231","article-title":"Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B\/C","volume":"48","author":"Efe","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0390","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/liv.13236","article-title":"Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0395","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/MEG.0000000000000424","article-title":"Autoimmune liver disease and concomitant extrahepatic autoimmune disease","volume":"27","author":"Muratori","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0400","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MCG.0b013e3181c74e0d","article-title":"Concurrent autoimmune diseases in patients with autoimmune hepatitis","volume":"44","author":"Teufel","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0405","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/apt.13210","article-title":"Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype","volume":"41","author":"Muratori","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.02.013_bb0410","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.51.2.259","article-title":"Establishment of standardised SLA\/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics","volume":"51","author":"Baeres","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.02.013_bb0415","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1572-0241.2002.05479.x","article-title":"Antibodies to soluble liver antigen\/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis","volume":"97","author":"Czaja","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0420","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/liv.12658","article-title":"Anti-SLA\/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis","volume":"35","author":"Zachou","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0425","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/MCG.0b013e3181587d18","article-title":"Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis","volume":"42","author":"Montano-Loza","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0430","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-230X-12-92","article-title":"Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature","volume":"12","author":"Invernizzi","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0435","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0440","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","article-title":"Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis","volume":"42","author":"Luth","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0445","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ajg.2015.139","article-title":"Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis","volume":"110","author":"Dhaliwal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0450","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis","volume":"40","author":"Czaja","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0455","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","article-title":"Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy","volume":"99","author":"Verma","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0460","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/00365521.2016.1253768","article-title":"Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis","volume":"52","author":"Puustinen","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0465","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","article-title":"Prognosis of histological cirrhosis in type 1 autoimmune hepatitis","volume":"110","author":"Roberts","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0470","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.20235","article-title":"Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis","volume":"39","author":"Czaja","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0475","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0480","first-page":"1","article-title":"Autoimmune hepatitis: progress from global immunosuppression to personalised regulatory T cell therapy","author":"Than","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0485","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0490","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/lt.21036","article-title":"Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis","volume":"13","author":"Ichai","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.autrev.2018.02.013_bb0495","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.21074","article-title":"Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly","volume":"43","author":"Czaja","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0500","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.24141","article-title":"Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis","volume":"53","author":"Yeoman","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0505","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0016-5085(88)90503-3","article-title":"Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis","volume":"95","author":"Czaja","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0510","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.21787","article-title":"Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease","volume":"46","author":"Montano-Loza","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0515","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/apt.12042","article-title":"Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs","volume":"36","author":"Selvarajah","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.02.013_bb0520","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gut.2010.235259","article-title":"British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis","volume":"60","author":"Gleeson","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.02.013_bb0525","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","article-title":"Rapidity of treatment response and outcome in type 1 autoimmune hepatitis","volume":"51","author":"Czaja","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0530","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2007.01153.x","article-title":"Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse","volume":"102","author":"Montano-Loza","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0535","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/hep.23924","article-title":"Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis","volume":"52","author":"Muratori","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.autrev.2018.02.013_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179074","article-title":"Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis","volume":"12","author":"Taubert","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2018.02.013_bb0545","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.dld.2016.06.018","article-title":"Predictive factors of poor response to therapy in Autoimmune hepatitis","volume":"48","author":"Muratori","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2036.2011.04690.x","article-title":"Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients","volume":"34","author":"Wang","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2018.02.013_bb0555","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bcpt.12788","article-title":"Enrichment of Genetic Variants in the Glucocorticoid Receptor Signalling Pathway in Autoimmune Hepatitis with Failure of Standard Treatment","volume":"121","author":"Eriksen","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0560","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0565","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0570","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004836-199312000-00012","article-title":"A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis","volume":"17","author":"Person","year":"1993","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0575","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","article-title":"Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis","volume":"46","author":"Malekzadeh","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2018.02.013_bb0580","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1572-0241.1999.00807.x","article-title":"Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis","volume":"94","author":"Fernandes","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0585","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","article-title":"Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis","volume":"21","author":"Sherman","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0590","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00365521.2016.1236398","article-title":"The use of tacrolimus in refractory autoimmune hepatitis in children and adults: a single center experience","volume":"52","author":"Al Taii","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0595","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/00365521.2015.1095351","article-title":"Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on tacrolimus therapy","volume":"51","author":"Than","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0600","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","article-title":"Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience","volume":"34","author":"Tannous","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.02.013_bb0605","first-page":"771","article-title":"Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial","volume":"90","author":"Van Thiel","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0610","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i23.3232","article-title":"Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis","volume":"13","author":"Larsen","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0615","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0620","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0625","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.4067\/S0034-98872011001100015","article-title":"Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome","volume":"139","author":"Carey","year":"2011","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.autrev.2018.02.013_bb0630","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0635","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jceh.2017.01.115","article-title":"Role of allopurinol in optimizing thiopurine therapy in patients with autoimmune hepatitis: a review","volume":"7","author":"Deswal","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0640","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0168-8278(00)00095-7","article-title":"Duration of immunosuppressive therapy in autoimmune hepatitis","volume":"34","author":"Kanzler","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0645","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.1840030510","article-title":"Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis","volume":"3","author":"Hegarty","year":"1983","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0650","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM198101013040102","article-title":"Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis","volume":"304","author":"Czaja","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.02.013_bb0655","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0016-5085(87)90862-6","article-title":"Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis","volume":"92","author":"Czaja","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0660","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0665","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the Liver","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0670","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline","volume":"66","author":"European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0675","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0680","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis","volume":"38","author":"Broome","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.02.013_bb0685","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0690","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","author":"Claessen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0695","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1572-0241.2004.04067.x","article-title":"Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis","volume":"99","author":"Burak","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0700","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/003655202760373434","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation","volume":"37","author":"Boberg","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0705","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1478-3231.2011.02614.x","article-title":"Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort","volume":"32","author":"de Valle","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0710","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstrom","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0715","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0720","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0725","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis","volume":"40","author":"Rupp","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.02.013_bb0730","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","author":"de Vries","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0735","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0740","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2018.02.013_bb0745","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.1840100406","article-title":"Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis","volume":"10","author":"Wiesner","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0750","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.autrev.2018.02.013_bb0755","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study","volume":"37","author":"de Vries","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0760","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12072-011-9260-4","article-title":"Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature","volume":"5","author":"Singal","year":"2011","journal-title":"Hepatol Int"},{"key":"10.1016\/j.autrev.2018.02.013_bb0765","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis","volume":"134","author":"Bjornsson","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0770","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weismuller","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0775","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","article-title":"Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"100","author":"Floreani","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0780","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0785","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/apt.13516","article-title":"Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD","volume":"43","author":"Fevery","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.02.013_bb0790","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","article-title":"Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy","volume":"134","author":"Ghazale","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0795","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00261-016-0903-8","article-title":"Imaging of autoimmune biliary disease","volume":"42","author":"Yeh","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.autrev.2018.02.013_bb0800","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/j.1572-0241.2006.00772.x","article-title":"Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis","volume":"101","author":"Mendes","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0805","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.26977","article-title":"Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis","volume":"59","author":"Boonstra","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0810","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","author":"Corpechot","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0815","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1053\/j.gastro.2014.04.058","article-title":"Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations","volume":"147","author":"Ehlken","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0820","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164224","article-title":"Validation of transient elastography and comparison with spleen length measurement for staging of fibrosis and clinical prognosis in primary sclerosing cholangitis","volume":"11","author":"Ehlken","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2018.02.013_bb0825","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00261-016-0847-z","article-title":"Early peribiliary hyperenhancement on MRI in patients with primary sclerosing cholangitis: significance and association with the mayo risk score","volume":"42","author":"Ni Mhuircheartaigh","year":"2017","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.autrev.2018.02.013_bb0830","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/jgh.13263","article-title":"Performance of magnetic resonance elastography in primary sclerosing cholangitis","volume":"31","author":"Eaton","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0835","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0840","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2015.06.008","article-title":"Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis","volume":"63","author":"de Vries","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0845","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.28963","article-title":"Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study","volume":"65","author":"de Vries","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0850","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","article-title":"Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis","volume":"51","author":"Rudolph","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0855","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.51.4.562","article-title":"Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population","volume":"51","author":"Ponsioen","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.02.013_bb0860","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s002610000098","article-title":"Evaluation of a modified cholangiographic classification system for primary sclerosing cholangitis","volume":"26","author":"Rajaram","year":"2001","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.autrev.2018.02.013_bb0865","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1055\/s-0030-1255527","article-title":"Validation of a cholangiographic prognostic model in primary sclerosing cholangitis","volume":"42","author":"Ponsioen","year":"2010","journal-title":"Endoscopy"},{"key":"10.1016\/j.autrev.2018.02.013_bb0870","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0875","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/0016-5085(91)90673-9","article-title":"Natural history and prognostic variables in primary sclerosing cholangitis","volume":"100","author":"Farrant","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0880","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/0016-5085(92)91449-E","article-title":"Primary sclerosing cholangitis: refinement and validation of survival models","volume":"103","author":"Dickson","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0885","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/jhep.2002.31872","article-title":"Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis","volume":"35","author":"Boberg","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0890","first-page":"1","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"0","author":"de Vries","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.02.013_bb0895","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2017.01.019","article-title":"Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis","volume":"66","author":"Vesterhus","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0900","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003510","article-title":"Evaluation of biliary calprotectin as a biomarker in primary sclerosing cholangitis","volume":"95","author":"Gauss","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2018.02.013_bb0905","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.12.002","article-title":"Gut-liver immunity","volume":"64","author":"Trivedi","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0910","first-page":"1","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"0","author":"Trivedi","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.02.013_bb0915","first-page":"587","volume":"463","author":"Time for the epigenome","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2018.02.013_bb0920","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0037-1603324","article-title":"Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis","volume":"37","author":"Cheung","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0925","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-0034-1383725","article-title":"Genetics and epigenetics of primary biliary cirrhosis","volume":"34","author":"Bianchi","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.autrev.2018.02.013_bb0930","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.autrev.2018.02.013_bb0935","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","article-title":"Multitarget stool DNA testing for colorectal-cancer screening","volume":"370","author":"Imperiale","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.02.013_bb0940","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/genes5030821","article-title":"DNA methylation biomarkers: cancer and beyond","volume":"5","author":"Mikeska","year":"2014","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.autrev.2018.02.013_bb0945","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2014.00438","article-title":"Potential of epigenetic therapies in non-cancerous conditions","volume":"5","author":"Mau","year":"2014","journal-title":"Front Genet"},{"key":"10.1016\/j.autrev.2018.02.013_bb0950","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.02.013_bb0955","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0960","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2018.02.013_bb0965","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","article-title":"Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis","volume":"44","author":"Azemoto","year":"2009","journal-title":"J Gastroenterol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T02:43:40Z","timestamp":1720406620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218301538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":193,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1568997218301538"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.02.013","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Support of precision medicine through risk-stratification in autoimmune liver diseases \u2013 histology, scoring systems, and non-invasive markers","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}